S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
Log in
NYSE:TAK

Takeda Pharmaceutical Competitors

$17.44
-0.46 (-2.57 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$17.25
Now: $17.44
$17.51
50-Day Range
$17.83
MA: $18.37
$18.97
52-Week Range
$12.43
Now: $17.44
$20.42
Volume4.13 million shs
Average Volume2.35 million shs
Market Capitalization$54.98 billion
P/E Ratio58.14
Dividend Yield3.99%
Beta1.01

Competitors

Takeda Pharmaceutical (NYSE:TAK) Vs. NVS, MRK, PFE, ABT, ABBV, and LLY

Should you be buying TAK stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Takeda Pharmaceutical, including Novartis (NVS), Merck & Co., Inc. (MRK), Pfizer (PFE), Abbott Laboratories (ABT), AbbVie (ABBV), and Eli Lilly and (LLY).

Takeda Pharmaceutical (NYSE:TAK) and Novartis (NYSE:NVS) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk and institutional ownership.

Institutional and Insider Ownership

3.4% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 9.9% of Novartis shares are owned by institutional investors. 0.0% of Novartis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Dividends

Takeda Pharmaceutical pays an annual dividend of $0.72 per share and has a dividend yield of 4.1%. Novartis pays an annual dividend of $2.01 per share and has a dividend yield of 2.1%. Takeda Pharmaceutical pays out 40.4% of its earnings in the form of a dividend. Novartis pays out 38.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Risk and Volatility

Takeda Pharmaceutical has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500. Comparatively, Novartis has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500.

Profitability

This table compares Takeda Pharmaceutical and Novartis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Takeda Pharmaceutical3.04%13.46%5.02%
Novartis14.71%24.39%10.59%

Earnings & Valuation

This table compares Takeda Pharmaceutical and Novartis' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Takeda Pharmaceutical$30.20 billion1.82$407.02 million$1.789.80
Novartis$47.50 billion4.61$11.73 billion$5.2418.25

Novartis has higher revenue and earnings than Takeda Pharmaceutical. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Takeda Pharmaceutical and Novartis, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Takeda Pharmaceutical00103.00
Novartis22602.40

Takeda Pharmaceutical currently has a consensus price target of $30.00, suggesting a potential upside of 72.02%. Novartis has a consensus price target of $114.00, suggesting a potential upside of 19.21%. Given Takeda Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe Takeda Pharmaceutical is more favorable than Novartis.

Summary

Novartis beats Takeda Pharmaceutical on 11 of the 16 factors compared between the two stocks.

Takeda Pharmaceutical (NYSE:TAK) and Merck & Co., Inc. (NYSE:MRK) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Institutional and Insider Ownership

3.4% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 72.9% of Merck & Co., Inc. shares are held by institutional investors. 0.3% of Merck & Co., Inc. shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Dividends

Takeda Pharmaceutical pays an annual dividend of $0.72 per share and has a dividend yield of 4.1%. Merck & Co., Inc. pays an annual dividend of $2.60 per share and has a dividend yield of 3.1%. Takeda Pharmaceutical pays out 40.4% of its earnings in the form of a dividend. Merck & Co., Inc. pays out 50.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Merck & Co., Inc. has raised its dividend for 1 consecutive years. Takeda Pharmaceutical is clearly the better dividend stock, given its higher yield and lower payout ratio.

Risk & Volatility

Takeda Pharmaceutical has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500.

Profitability

This table compares Takeda Pharmaceutical and Merck & Co., Inc.'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Takeda Pharmaceutical3.04%13.46%5.02%
Merck & Co., Inc.24.33%53.83%16.83%

Earnings and Valuation

This table compares Takeda Pharmaceutical and Merck & Co., Inc.'s gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Takeda Pharmaceutical$30.20 billion1.82$407.02 million$1.789.80
Merck & Co., Inc.$46.84 billion4.50$9.84 billion$5.1916.07

Merck & Co., Inc. has higher revenue and earnings than Takeda Pharmaceutical. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for Takeda Pharmaceutical and Merck & Co., Inc., as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Takeda Pharmaceutical00103.00
Merck & Co., Inc.021202.86

Takeda Pharmaceutical currently has a consensus price target of $30.00, suggesting a potential upside of 72.02%. Merck & Co., Inc. has a consensus price target of $95.3571, suggesting a potential upside of 14.36%. Given Takeda Pharmaceutical's stronger consensus rating and higher probable upside, equities research analysts plainly believe Takeda Pharmaceutical is more favorable than Merck & Co., Inc..

Summary

Merck & Co., Inc. beats Takeda Pharmaceutical on 11 of the 17 factors compared between the two stocks.

Takeda Pharmaceutical (NYSE:TAK) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Institutional and Insider Ownership

3.4% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 67.4% of Pfizer shares are held by institutional investors. 0.1% of Pfizer shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Dividends

Takeda Pharmaceutical pays an annual dividend of $0.72 per share and has a dividend yield of 4.1%. Pfizer pays an annual dividend of $1.52 per share and has a dividend yield of 4.1%. Takeda Pharmaceutical pays out 40.4% of its earnings in the form of a dividend. Pfizer pays out 51.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Pfizer has raised its dividend for 1 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Risk & Volatility

Takeda Pharmaceutical has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500.

Profitability

This table compares Takeda Pharmaceutical and Pfizer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Takeda Pharmaceutical3.04%13.46%5.02%
Pfizer17.85%24.88%9.32%

Earnings and Valuation

This table compares Takeda Pharmaceutical and Pfizer's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Takeda Pharmaceutical$30.20 billion1.82$407.02 million$1.789.80
Pfizer$51.75 billion3.94$16.27 billion$2.9512.44

Pfizer has higher revenue and earnings than Takeda Pharmaceutical. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for Takeda Pharmaceutical and Pfizer, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Takeda Pharmaceutical00103.00
Pfizer010402.29

Takeda Pharmaceutical currently has a consensus price target of $30.00, suggesting a potential upside of 72.02%. Pfizer has a consensus price target of $40.0714, suggesting a potential upside of 9.19%. Given Takeda Pharmaceutical's stronger consensus rating and higher probable upside, equities research analysts plainly believe Takeda Pharmaceutical is more favorable than Pfizer.

Summary

Pfizer beats Takeda Pharmaceutical on 12 of the 17 factors compared between the two stocks.

Takeda Pharmaceutical (NYSE:TAK) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Institutional and Insider Ownership

3.4% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 72.6% of Abbott Laboratories shares are held by institutional investors. 1.7% of Abbott Laboratories shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Dividends

Takeda Pharmaceutical pays an annual dividend of $0.72 per share and has a dividend yield of 4.1%. Abbott Laboratories pays an annual dividend of $1.80 per share and has a dividend yield of 1.6%. Takeda Pharmaceutical pays out 40.4% of its earnings in the form of a dividend. Abbott Laboratories pays out 55.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Abbott Laboratories has raised its dividend for 49 consecutive years. Takeda Pharmaceutical is clearly the better dividend stock, given its higher yield and lower payout ratio.

Risk & Volatility

Takeda Pharmaceutical has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500.

Profitability

This table compares Takeda Pharmaceutical and Abbott Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Takeda Pharmaceutical3.04%13.46%5.02%
Abbott Laboratories10.50%18.19%8.29%

Earnings and Valuation

This table compares Takeda Pharmaceutical and Abbott Laboratories' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Takeda Pharmaceutical$30.20 billion1.82$407.02 million$1.789.80
Abbott Laboratories$31.90 billion6.18$3.69 billion$3.2434.35

Abbott Laboratories has higher revenue and earnings than Takeda Pharmaceutical. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for Takeda Pharmaceutical and Abbott Laboratories, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Takeda Pharmaceutical00103.00
Abbott Laboratories121302.75

Takeda Pharmaceutical currently has a consensus price target of $30.00, suggesting a potential upside of 72.02%. Abbott Laboratories has a consensus price target of $115.6875, suggesting a potential upside of 3.94%. Given Takeda Pharmaceutical's stronger consensus rating and higher probable upside, equities research analysts plainly believe Takeda Pharmaceutical is more favorable than Abbott Laboratories.

Summary

Abbott Laboratories beats Takeda Pharmaceutical on 12 of the 17 factors compared between the two stocks.

Takeda Pharmaceutical (NYSE:TAK) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Institutional and Insider Ownership

3.4% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 67.5% of AbbVie shares are held by institutional investors. 0.1% of AbbVie shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Dividends

Takeda Pharmaceutical pays an annual dividend of $0.72 per share and has a dividend yield of 4.1%. AbbVie pays an annual dividend of $5.20 per share and has a dividend yield of 4.7%. Takeda Pharmaceutical pays out 40.4% of its earnings in the form of a dividend. AbbVie pays out 58.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. AbbVie has raised its dividend for 49 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Risk & Volatility

Takeda Pharmaceutical has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500.

Profitability

This table compares Takeda Pharmaceutical and AbbVie's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Takeda Pharmaceutical3.04%13.46%5.02%
AbbVie18.16%439.24%13.22%

Earnings and Valuation

This table compares Takeda Pharmaceutical and AbbVie's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Takeda Pharmaceutical$30.20 billion1.82$407.02 million$1.789.80
AbbVie$33.27 billion5.87$7.88 billion$8.9412.36

AbbVie has higher revenue and earnings than Takeda Pharmaceutical. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for Takeda Pharmaceutical and AbbVie, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Takeda Pharmaceutical00103.00
AbbVie141602.71

Takeda Pharmaceutical currently has a consensus price target of $30.00, suggesting a potential upside of 72.02%. AbbVie has a consensus price target of $112.50, suggesting a potential upside of 1.79%. Given Takeda Pharmaceutical's stronger consensus rating and higher probable upside, equities research analysts plainly believe Takeda Pharmaceutical is more favorable than AbbVie.

Summary

AbbVie beats Takeda Pharmaceutical on 12 of the 17 factors compared between the two stocks.

Takeda Pharmaceutical (NYSE:TAK) and Eli Lilly and (NYSE:LLY) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Earnings and Valuation

This table compares Takeda Pharmaceutical and Eli Lilly and's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Takeda Pharmaceutical$30.20 billion1.82$407.02 million$1.789.80
Eli Lilly and$22.32 billion8.18$8.32 billion$6.0431.58

Eli Lilly and has lower revenue, but higher earnings than Takeda Pharmaceutical. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

3.4% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 75.6% of Eli Lilly and shares are held by institutional investors. 0.1% of Eli Lilly and shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Takeda Pharmaceutical and Eli Lilly and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Takeda Pharmaceutical3.04%13.46%5.02%
Eli Lilly and24.01%166.45%15.18%

Risk & Volatility

Takeda Pharmaceutical has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, Eli Lilly and has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for Takeda Pharmaceutical and Eli Lilly and, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Takeda Pharmaceutical00103.00
Eli Lilly and05912.73

Takeda Pharmaceutical currently has a consensus price target of $30.00, suggesting a potential upside of 72.02%. Eli Lilly and has a consensus price target of $172.2143, suggesting a potential downside of 9.73%. Given Takeda Pharmaceutical's stronger consensus rating and higher probable upside, equities research analysts plainly believe Takeda Pharmaceutical is more favorable than Eli Lilly and.

Dividends

Takeda Pharmaceutical pays an annual dividend of $0.72 per share and has a dividend yield of 4.1%. Eli Lilly and pays an annual dividend of $2.96 per share and has a dividend yield of 1.6%. Takeda Pharmaceutical pays out 40.4% of its earnings in the form of a dividend. Eli Lilly and pays out 49.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Eli Lilly and has raised its dividend for 1 consecutive years. Takeda Pharmaceutical is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Eli Lilly and beats Takeda Pharmaceutical on 11 of the 18 factors compared between the two stocks.


Takeda Pharmaceutical Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Novartis logo
NVS
Novartis
1.7$95.63-1.1%$218.87 billion$47.50 billion30.95Analyst Report
Merck & Co., Inc. logo
MRK
Merck & Co., Inc.
2.2$83.38-1.5%$210.95 billion$46.84 billion18.45Heavy News Reporting
Pfizer logo
PFE
Pfizer
2.6$36.70-0.1%$204.88 billion$51.75 billion23.68
Abbott Laboratories logo
ABT
Abbott Laboratories
2.6$111.30-1.1%$197.26 billion$31.90 billion58.89
AbbVie logo
ABBV
AbbVie
2.9$110.52-1.0%$195.12 billion$33.27 billion23.37Analyst Revision
Eli Lilly and logo
LLY
Eli Lilly and
2.0$190.77-2.1%$182.49 billion$22.32 billion31.17Increase in Short Interest
Novo Nordisk A/S logo
NVO
Novo Nordisk A/S
1.1$72.03-1.4%$169.62 billion$18.30 billion27.08Analyst Report
Decrease in Short Interest
Bristol-Myers Squibb logo
BMY
Bristol-Myers Squibb
2.5$66.54-0.8%$150.56 billion$26.15 billion-604.85
AZN
AstraZeneca
2.1$51.34-0.1%$134.75 billion$24.38 billion53.48Analyst Report
SNY
Sanofi
1.8$49.39-0.7%$120.30 billion$40.00 billion21.11Analyst Report
GlaxoSmithKline logo
GSK
GlaxoSmithKline
1.4$38.47-0.8%$94.52 billion$43.10 billion11.84Analyst Report
Zoetis logo
ZTS
Zoetis
1.8$161.56-0.4%$76.78 billion$6.26 billion47.94Increase in Short Interest
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.4$225.55-0.3%$58.65 billion$4.16 billion28.48Increase in Short Interest
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.4$517.93-0.0%$54.62 billion$7.86 billion18.93
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.8$156.70-0.0%$34.29 billion$4.99 billion36.61Decrease in Short Interest
BeiGene logo
BGNE
BeiGene
1.3$345.00-2.6%$31.37 billion$428.21 million-17.07Analyst Revision
GMAB
Genmab A/S
1.0$44.40-0.6%$28.07 billion$804.57 million34.42Analyst Report
Decrease in Short Interest
Royalty Pharma logo
RPRX
Royalty Pharma
1.4$51.95-1.3%$19.39 billionN/A0.00Dividend Increase
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.6$166.36-0.8%$19.33 billion$219.75 million-21.25
Catalent logo
CTLT
Catalent
1.7$115.50-0.2%$19.02 billion$3.09 billion73.57
CureVac logo
CVAC
CureVac
0.6$100.35-0.2%$17.66 billionN/A0.00
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$78.72-0.2%$17.37 billion$1.30 billion21.51Insider Selling
Increase in Short Interest
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$82.97-1.9%$15.06 billion$1.70 billion18.99
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.4$31.51-0.4%$14.87 billion$3.07 billion-55.28Decrease in Short Interest
Grifols logo
GRFS
Grifols
1.2$19.08-0.4%$13.12 billion$5.71 billion17.04
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.4$11.96-3.8%$12.61 billion$16.89 billion-3.25
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.3$71.06-1.3%$11.89 billion$2.32 billion58.73
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.4$214.47-0.3%$10.15 billion$3.34 million-27.85Analyst Report
Zai Lab logo
ZLAB
Zai Lab
1.2$170.90-4.1%$9.93 billion$12.98 million-56.40
Bausch Health Companies logo
BHC
Bausch Health Companies
1.5$26.37-0.2%$9.37 billion$8.60 billion-4.84Analyst Report
Decrease in Short Interest
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
1.9$167.71-1.1%$9.34 billion$2.16 billion52.91Unusual Options Activity
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.0$61.28-0.1%$8.57 billion$1.12 billion127.67
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.6$53.66-1.5%$8.53 billion$339.08 million-31.20Analyst Revision
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$157.93-2.6%$8.44 billion$14.98 million-19.24Analyst Revision
BBIO
BridgeBio Pharma
1.6$68.61-1.6%$8.42 billion$40.56 million-20.12Analyst Downgrade
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.3$80.74-2.6%$8.30 billion$87.99 million-96.12Insider Selling
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.3$137.97-1.4%$8.22 billion$103.71 million-31.43
United Therapeutics logo
UTHR
United Therapeutics
1.3$172.82-3.2%$7.20 billion$1.45 billion16.35
TG Therapeutics logo
TGTX
TG Therapeutics
1.4$49.62-3.2%$6.98 billion$150,000.00-23.41Analyst Revision
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$90.32-0.5%$6.88 billion$380.83 million-11.55
Allakos logo
ALLK
Allakos
1.2$128.51-0.0%$6.75 billionN/A-46.90Analyst Report
Unusual Options Activity
Galapagos logo
GLPG
Galapagos
1.3$100.01-1.7%$6.57 billion$1.00 billion-15.15
Perrigo logo
PRGO
Perrigo
2.4$43.71-2.2%$6.29 billion$4.84 billion-728.38
TPTX
Turning Point Therapeutics
1.5$131.60-4.1%$6.17 billionN/A-37.49Analyst Revision
SDGR
Schrödinger
1.3$90.89-2.2%$6.15 billion$85.54 million0.00Insider Selling
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.2$21.84-6.6%$5.99 billion$182.24 million-18.99
Emergent BioSolutions logo
EBS
Emergent BioSolutions
1.5$106.29-0.3%$5.63 billion$1.11 billion34.18
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$100.99-1.5%$5.63 billion$66.51 million18.63
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
1.6$84.91-8.1%$5.09 billionN/A-6.92Heavy News Reporting
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.2$91.38-5.9%$5.01 billion$6.87 million-8.83
This page was last updated on 1/18/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.